Author:
Fradet Y.,Bellmunt J.,Vaughn D.J.,Lee J.L.,Fong L.,Vogelzang N.J.,Climent M.A.,Petrylak D.P.,Choueiri T.K.,Necchi A.,Gerritsen W.,Gurney H.,Quinn D.I.,Culine S.,Sternberg C.N.,Nam K.,Frenkl T.L.,Perini R.F.,de Wit R.,Bajorin D.F.
Funder
Merck Sharp & Dohme Corp.
Merck & Co.
Inc.
Reference18 articles.
1. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial;Seiwert;Lancet Oncol,2016
2. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study;Plimack;Lancet Oncol,2017
3. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017
4. KEYTRUDA® (Pembrolizumab) for Injection, for Intravenous Use [prescribing information],2019
5. Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer;Vaughn;JCO,2018